How to access Rituxan from Pakistan, the named-patient import pathway, 2026

*Clinically reviewed by Reserve Meds AI Clinical and Regulatory Review (see /trust). Last reviewed 2026-05-13.

A Pakistani patient with CD20-positive non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis in combination with methotrexate, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris may receive a prescription for Rituxan (rituximab) from their treating oncologist, hematologist, or rheumatologist depending on indication. Rituxan is FDA-approved in the United States and manufactured by Genentech and Biogen (Roche). It is a chimeric CD20-directed monoclonal antibody administered by intravenous infusion. Local availability of Rituxan in Pakistan can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through DRAP remains a legitimate route for the patient whose physician has already prescribed the drug.

This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.

The clinical situation

Rituxan is a chimeric CD20-directed monoclonal antibody. Mechanism: a chimeric IgG1 monoclonal antibody that binds CD20 on B-cells and mediates B-cell depletion through antibody-dependent and complement-dependent mechanisms. Dosing: indication-specific dosing by intravenous infusion or, for Rituxan Hycela, subcutaneously after a first IV dose, per FDA labeling. Baseline workup per FDA labeling includes hepatitis B serologies (HBsAg and anti-HBc), complete blood count, immunoglobulin levels where indicated, and infection screen including tuberculosis. The FDA boxed warning covers fatal infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Other important warnings include infusion reactions including fatal infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Your specialist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.

Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.

Is Rituxan legally importable into Pakistan?

Yes, through the Drug Regulatory Authority of Pakistan (DRAP) named-patient and personal-use import framework, coordinated with the treating facility's pharmacy. Pakistan has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.

The DRAP named-patient route allows a Pakistani-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.

How the pathway works, step by step

1. Consultation with your treating specialist. The prescribing decision is clinical. Your specialist documents the indication, prior therapies where relevant, and rationale for Rituxan.
2. Baseline screening. Hepatitis B serologies (HBsAg and anti-HBc), complete blood count, immunoglobulin levels where indicated, and infection screen including tuberculosis are confirmed and documented.
3. DRAP named-patient application. Your specialist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Genentech and Biogen (Roche)'s authorised distribution under DSCSA chain-of-custody.
5. Cold-chain shipment. Rituxan requires refrigerated transport at 2 to 8 degrees Celsius. Shipments include temperature-monitored packaging with continuous loggers and tamper-evident seals.
6. Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your specialist initiates therapy.

What documentation your physician needs

Your physician will typically need to provide:

• A clinical rationale letter confirming diagnosis, prior therapies where relevant, and Rituxan as the indicated next step
• Verification of their Pakistani medical licence
• A patient identifier, anonymised reference where privacy is preferred
• Documented pre-treatment screening consistent with FDA labeling (see above)
• The planned dosing regimen (indication-specific dosing by intravenous infusion or, for Rituxan Hycela, subcutaneously after a first IV dose, per FDA labeling)
• A monitoring plan covering HBV screen, infusion-reaction premedication, and indication-specific dosing schedule

Reserve Meds provides a physician documentation kit tailored for CD20-directed monoclonal antibody therapies, including the templates DRAP reviewers commonly request.

Typical costs and indicative timing

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a single infusion (biosimilars often lower; full courses vary by indication) of Rituxan sits in an indicative 2026 band of approximately USD 4,500 to 8,000. International logistics, DRAP documentation handling, cold-chain shipping, and concierge coordination add incremental cost. The delivered quote we issue at intake shows each line separately.

Indicative timing for first dose after cohort intake opens is approximately 2 to 5 weeks from the moment a complete application is submitted, assuming the documentation package is clean on first pass. Refills ship on a rolling cadence aligned to the dosing schedule.

Where Reserve Meds fits in

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rituxan specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
• Documentation. Regulatory package tailored for your physician and for DRAP review, including CD20-directed monoclonal antibody class templates.
• Cold-chain logistics. Temperature-monitored, internationally tracked shipment to your named dispensing facility with continuous temperature loggers.
• Concierge case lead. A named point of contact for your family and your physician across the full case arc.

We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating specialist, and dispensing sits with the licensed Pakistani pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.

Frequently asked

Is this legal in Pakistan? Yes, when executed through the DRAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Pakistani tertiary centers.

What about the boxed warning? The FDA boxed warning on Rituxan covers fatal infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation, and progressive multifocal leukoencephalopathy. Your specialist performs the risk-benefit assessment, schedules monitoring, and counsels the patient per labeling. Reserve Meds does not make that clinical judgement, your physician does.

Will my private health insurance cover this? Cash-pay is the default posture. Cash-pay is the default posture in Pakistan; some employer plans cover specialty imports case-by-case. We supply documentation for your submission but do not process insurance claims.

How does cold-chain affect timing? Rituxan ships refrigerated. We use validated packaging with continuous temperature monitoring, and arrival temperature data is logged on every shipment.

What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Pakistani tertiary centers (Shaukat Khanum Memorial Cancer Hospital, Aga Khan University Hospital, and the Indus Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what DRAP reviewers commonly ask for.

Next step

For Rituxan coordination in Pakistan, start your case at the portal or message us on WhatsApp. Our concierge case lead will respond within 24 hours.

---

Composite case examples. This content is for general information and does not constitute medical advice.